An Economic Analysis of Global Policy Proposals to Prohibit Compensation of Blood Plasma Donors
Repository Usage Stats
© 2016 International Journal of the Economics of Business.Human blood plasma and its derivative therapies have been used therapeutically for more than 50 years, after first being widely used to treat injuries during World War II. In certain countries, manufacturers of these therapies – known as plasma-derived medicinal products (PDMPs) – compensate plasma donors, raising healthcare and ethical concerns among some parties. In particular, the World Health Organization has taken a strong advocacy position that compensation for blood donations should be eliminated worldwide. This review evaluates the key economic factors underlying the supply and demand for PDMPs and the evidence pointing to the policy options that are most likely to maintain a reliable supply of life-sustaining therapies. It concludes that compensated plasma donation is important for maintaining adequate and consistent supplies of plasma and limits the risk of under-treatment for the foreseeable future.
Published Version (Please cite this version)10.1080/13571516.2016.1182690
Publication InfoGrabowski, Henry G; & Manning, Richard L (2016). An Economic Analysis of Global Policy Proposals to Prohibit Compensation of Blood Plasma Donors. International Journal of the Economics of Business, 23(2). pp. 149-166. 10.1080/13571516.2016.1182690. Retrieved from http://hdl.handle.net/10161/12740.
This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.
More InfoShow full item record
Professor Emeritus of Economics
Professor Grabowski specializes in the investigation of economics in the pharmaceutical industry, government regulation of business, and the economics of innovation. His specific interests within these fields include intellectual property and generic competition issues, the effects of government policy actions, and the costs and returns to pharmaceutical R&D. He has been publishing research papers for over four decades, from his earlier work, “The Effects of Regulatory Policy on the Incentives